Eden Innovations Ltd Reports Strong Trial Results and Expansion
Key points
- Strong EdenCrete® trial results and regional expansion
- New appointments to drive EdenShield® growth in Australia and Europe
- US$2.90 million of OptiBlend® quotations issued during FY26
- Completed $4.05 million placement and achieved debt-free status
Full summary
Eden Innovations Ltd (ASX:EDE) reported significant progress in the quarter ended 30 June 2026, highlighted by strong trial results for its EdenCrete® product, particularly EdenCrete® Pz7, which saw exponential growth in installations. The company expanded its presence in the US and India, with positive trial results in Delhi indicating potential for large-scale adoption. Additionally, key appointments were made to drive the growth of EdenShield®, Eden's defense and infrastructure division. The company also reported US$2.90 million in OptiBlend® quotations issued during FY26, reflecting growing demand from US data center operators. A $4.05 million placement was completed, and the company achieved debt-free status by settling remaining loans and director fees.
Outlook
Eden enters FY2027 well-funded, with $5.2 million cash at bank, to accelerate commercialisation of EdenCrete®, OptiBlend® and EdenShield® technology lines.
Summary generated by a large language model. Please interpret with care.